ArticleJournal of molecular histology2025
Quercetin prevents sarcopenia by reversing oxidative stress and mitochondrial damage.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Interplay between frailty and cardiometabolic disorders: from pathophysiology to clinical implications.Cardiovascular diabetology · 2025Pooled it
- Quercetin attenuates deoxynivalenol-induced muscle developmental disorders in broilers by modulating the PI3K/Akt/mTOR pathway and reducing apoptosis.Poultry science · 2026Article
- Quercetin Can Alleviate ETECK88-Induced Oxidative Stress in Weaned Piglets by Inhibiting Quorum-Sensing Signal Molecule Autoinducer-2 Production in the Cecum.Antioxidants (Basel, Switzerland) · 2025Article
- Exposure to volatile organic compounds increases the risk of sarcopenia: Insights into association and mechanism.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the effectiveness of quercetin (QUE) in preventing sarcopenia via the PI3K/AKT signaling pathway. Thirty SD rats were categorized into three groups: a young control group (Y), an old control group (O), and an old QUE-supplemented group (O + QUE). Body weight and grip strength were monitored weekly during the experiment. Soleus and gastrocnemius muscle weights, gastrocnemius tissue pathological examination, cell apoptosis, and mitochondrial damage were evaluated using HE, TUNEL staining, electron microscopy, and JC-1 staining. Biochemical assays and molecular biology techniques (qPCR and Western blot) were used to assess oxidative stress markers and the expression of sarcopenia-related genes and proteins. QUE supplementation increased muscle weight and improved grip strength in aged rats. Furthermore, QUE supplementation alleviated tissue damage, apoptosis, enhanced antioxidant capacity, and decreased damage to oxidative stress and mitochondria in the gastrocnemius of old rats. Molecular assessments revealed downregulation of muscle degradation markers (MuRF1, Atrogen-1, Bnip3) and upregulation of PI3K/AKT pathway proteins, suggesting a mechanistic pathway through which QUE mitigates sarcopenia. QUE maybe modulate the PI3K/AKT pathway to alleviate oxidative stress, mitochondrial damage, and muscle degradation due to aging, highlighting its potential as a therapeutic agent against sarcopenia.
Indexed as
Identifiers
40208444What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.